Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a pill save your sight? new trial targets blinding eye disease

NCT ID NCT05949593

Disease control Sponsor: Belite Bio, Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether a daily pill called tinlarebant can slow the growth of geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. About 429 adults with the condition will receive either the drug or a placebo for up to 2 years. The main goal is to see if the drug reduces the rate of vision loss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tinlarebant (a tablet taken daily)
What this could lead to
If it works, this could slow vision loss from geographic atrophy, a leading cause of blindness in older adults.
What could go wrong
This is a late-stage trial, but the drug may not slow vision loss enough to matter. Side effects from daily medication are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 429 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects must have a confirmed diagnosis of GA with atrophic lesions in 1 or both eyes. * Minimum BCVA is required in the study eye Exclusion Criteria: * The presence of diabetic macular edema or macular disease in either eye. * Diabetic retinopathy more advanced than mild nonproliferative diabetic retinopathy, or any other retinal vascular disease in either eye. * Uncontrolled diagnosed glaucoma in the study eye

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Geographic atrophy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry age related macular degeneration Geographic Atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Geographic atrophy

Contacts and locations

Locations

  • Belite Study Site

    Phoenix, Arizona, 85020, United States

  • Belite Study Site

    Arcadia, California, 91007, United States

  • Belite Study Site

    Beverly Hills, California, 90211, United States

  • Belite Study Site

    Huntington Beach, California, 92467, United States

  • Belite Study Site

    Los Angeles, California, 90033, United States

  • Belite Study Site

    Palo Alto, California, 94303, United States

  • Belite Study Site

    San Diego, California, 92093, United States

  • Belite Study Site

    Lakeland, Florida, 33805, United States

  • Belite Study Site

    Hagerstown, Maryland, 21740, United States

  • Belite Study Site

    Saint Louis Park, Minnesota, 55416, United States

  • Belite Study Site

    Westbury, New York, 11590, United States

  • Belite Study Site

    Cary, North Carolina, 27511, United States

  • Belite Study Site

    Durham, North Carolina, 27710, United States

  • Belite Study Site

    Wake Forest, North Carolina, 27587, United States

  • Belite Study Site

    Portland, Oregon, 97239, United States

  • Belite Study Site

    Philadelphia, Pennsylvania, 19107, United States

  • Belite Study Site

    Sewickley, Pennsylvania, 15143, United States

  • Belite Study Site

    Germantown, Tennessee, 38138, United States

  • Belite Study Site

    Abilene, Texas, 79606, United States

  • Belite Study Site

    Dallas, Texas, 75231, United States

  • Belite Study Site

    San Antonio, Texas, 78240, United States

  • Belite Study Site

    Warrenton, Virginia, 20186, United States

  • Belite Study Site

    Chatswood, New South Wales, 2067, Australia

  • Belite Study Site

    Strathfield, New South Wales, 2135, Australia

  • Belite Study Site

    Brisbane, Queensland, 4101, Australia

  • Belite Study Site

    Adelaide, South Australia, 5000, Australia

  • Belite Study Site

    East Melbourne, Victoria, 3002, Australia

  • Belite Study Site

    Crawley, Western Australia, 6009, Australia

  • Belite Study Site

    Beijing, Beijing Municipality, 100044, China

  • Belite Study Site

    Chengdu, Sichuan, 610093, China

  • Belite Study Site

    Beijing, 10005, China

  • Belite Study Site

    Beijing, 100730, China

  • Belite Study Site

    Guandong, 510060, China

  • Belite Study Site

    Zhejiang, 325027, China

  • Belite Study Site

    Ostrava, 70852, Czechia

  • Belite Study Site

    Prague, 14000, Czechia

  • Belite Study Site

    Prague, 14059, Czechia

  • Belite Study Site

    Dijon, 21000, France

  • Belite Study Site

    Écully, 69130, France

  • Belite Study Site

    Lyon, 69317, France

  • Belite Study Site

    Marseille, 130008, France

  • Belite Study Site

    Basel, 4031, Switzerland

  • Belite Study Site

    Lausanne, 1001, Switzerland

  • Belite Study Site

    Taichung, 40447, Taiwan

  • Belite Study Site

    Taipei, 100, Taiwan

  • Belite Study Site

    Taoyuan, 33305, Taiwan

  • Belite Study Site

    Great Yarmouth, NR31 6LA, United Kingdom

  • Belite Study Site

    Harrow, HA1 3UJ, United Kingdom

  • Belite Study Site

    London, EC1V 2PD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.